- Home
- NEGG vs INZY Comparison
NEGG vs INZY Comparison
Compare NEGG & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- INZY
- Stock Information
- Founded
- NEGG 2001
- INZY 2015
- Country
- NEGG United States
- INZY United States
- Employees
- NEGG N/A
- INZY N/A
- Industry
- NEGG Other Specialty Stores
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- INZY Health Care
- Exchange
- NEGG Nasdaq
- INZY Nasdaq
- Market Cap
- NEGG 122.3M
- INZY 256.3M
- IPO Year
- NEGG 2010
- INZY 2020
- Fundamental
- Price
- NEGG $16.83
- INZY N/A
- Analyst Decision
- NEGG
- INZY Buy
- Analyst Count
- NEGG 0
- INZY 9
- Target Price
- NEGG N/A
- INZY $15.22
- AVG Volume (30 Days)
- NEGG 1.3M
- INZY 989.2K
- Earning Date
- NEGG 08-28-2025
- INZY 08-05-2025
- Dividend Yield
- NEGG N/A
- INZY N/A
- EPS Growth
- NEGG N/A
- INZY N/A
- EPS
- NEGG N/A
- INZY N/A
- Revenue
- NEGG $1,235,576,000.00
- INZY N/A
- Revenue This Year
- NEGG N/A
- INZY N/A
- Revenue Next Year
- NEGG N/A
- INZY N/A
- P/E Ratio
- NEGG N/A
- INZY N/A
- Revenue Growth
- NEGG N/A
- INZY N/A
- 52 Week Low
- NEGG $3.32
- INZY $0.72
- 52 Week High
- NEGG $26.40
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- NEGG 69.10
- INZY 82.67
- Support Level
- NEGG $15.00
- INZY $3.94
- Resistance Level
- NEGG $17.74
- INZY $3.97
- Average True Range (ATR)
- NEGG 2.00
- INZY 0.01
- MACD
- NEGG 0.44
- INZY -0.08
- Stochastic Oscillator
- NEGG 90.44
- INZY 100.00
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.